1	
2	Ezetimibe and Atherosclerotic Cardiovascular Disease:
3	A Systematic Review and Meta-Analyses
4	
5	
6	
7	Fatemeh Omidi ¹ , Maryam Rahmannia ² , Parsa Mohammadsharifi ³ , Mohammad Javad Nasiri ^{2*}
8	and Tala Sarmastzadeh ^{2*}
9	
10	
11	Department of Condicions, Incom Hannitel Chabid Debeshti Heinersity of Medical Coinness Takan Inco
12 13	² School of Medicine. Shahid Beheshti University of Medical Sciences, Tehran, Iran
14	³ School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran
15	
16	
17	
18	
10	
20	Correspondence:
21	Tala Sarmastzadeh, MD, MPH
22	Email: <u>t.sarmastzadeh@sbmu.ac.ir</u>
23 27	Mohammad Javad Nasırı, PhD, MPH
27	
25	
26	
77	
27	
28	
29	
30	
31	

32 Abstract:

33

Introduction: Individuals diagnosed with atherosclerotic cardiovascular disease (ASCVD), particularly those who have experienced acute coronary syndrome (ACS) within the past year, are at a heightened risk of recurrent cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) levels has been proven effective in reducing this risk. However, there is a lack of a comprehensive meta-analysis investigating the LDL-C-lowering effectiveness and coronary atherosclerotic plaque compositions of Ezetimibe. This study aims to address this gap in knowledge.

41

42 **Methods:** We conducted a systematic review of randomized controlled trials that 43 evaluated the LDL-C-lowering efficacy and coronary atherosclerotic plaques efficacy of 44 ezetimibe in patients with ASCVD. We searched relevant databases, including 45 MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, for 46 publications from database inception until Jul 2023. Meta-analyses were performed to 47 assess the LDL-C-lowering and coronary atherosclerotic plaques efficacy of ezetimibe in 48 the overall ASCVD population.

49

Results: The meta-analysis included a total of 20 eligible studies. Our findings revealed 50 that combination therapy of ezetimibe with statins resulted in a more substantial absolute 51 reduction in LDL-C compared to statin monotherapy (mean difference of (-14.06 mg/dL; 52 95% confidence interval [CI] -18.0 to -10.0; p = 0.0001) after 6-12 months of treatment 53 (or at a time point nearest to 6 -12months). Moreover, the subgroups analysis indicates 54 that the intervention measures were effective in reducing the volume of fibro-fatty plaque 55 (FFP) when compared to the control group [weighted mean difference (WMD) = -1.01, 56 95% confidence interval (CI) (-3.6 and 1.6), and p = 0.003], necrotic core (NC) volume 57 [WMD =-5.41, 95% CI(-13.3 and 2.5), and p = 0.35], and change dense calcification 58 59 (change DC) volume [WMD =-1.14, 95% CI (- 1.4 and -0.8), and p = 0.62] between the treatment group and the control group. 60

61

62 Conclusions: Our study indicates that the addition of ezetimibe to statin therapy results 63 in a modest yet significant further reduction in LDL-C compared to statin monotherapy. 64 Ezetimibe led to a significant reduction in FFP volume; however, there were no 65 statistically significant differences observed for NC, or change DC volumes.

66

67

⁶⁸ Keywords: Ezetimibe, cardiovascular disease, low-density lipoprotein cholesterol, systematic review

70 Introduction:

Atherosclerotic cardiovascular disease (ACD) is the leading cause of mortality 71 worldwide. ACD is primarily caused by elevated concentrations of low-density 72 lipoprotein cholesterol (LDL-C) [1, 2]. To prevent future cardiovascular events, it 73 is highly recommended to focus on the development of novel drugs that target and 74 effectively lower lipoprotein levels. The use of tolerated statins is recommended 75 for reducing LDL-C in patients with ACD. However, it is important to note that 76 even with statin therapy, additional lipid-lowering therapies may be necessary for 77 many patients with clinical ACD. Ezetimibe, a new cholesterol absorption inhibitor 78 drug, has demonstrated the ability to further lower LDL-C levels [3-5]. In a 79 randomized controlled trial, it was demonstrated that the combination of ezetimibe 80 with stating significantly reduces levels of LDL-C [6]. Additionally, the 81 combination of ezetimibe and stating leads to a substantial decrease in coronary 82 plaque volume compared to statin treatment alone [7]. Although the effectiveness 83 of ezetimibe in treating ACD has been acknowledged, there is an absence of a 84 85 comprehensive meta-analysis regarding the efficacy of ezetimibe in LDL-C lowering in ACD patients. Hence, the objective of this study was to conduct a 86 systematic evaluation of the effectiveness of ezetimibe in LDL-C lowering in ACD 87 patients, to offer valuable insights for therapeutic approaches. 88

89

90

91 Methods:

92 Search strategy

We conducted a comprehensive search in Pubmed/MEDLINE, EMBASE, and
Cochrane Library to identify relevant studies published until July 1, 2023, that

reported on the efficacy and effectiveness of ezetimibe in patients with ACD. The
search terms used were ezetimibe, coronary artery, atherosclerosis, and
randomized controlled trial. Only studies published in English were included. This
study adhered to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses statement (PRISMA) for its design and reporting (Prospero pending ID:
449721) [8].

101 Study Selection

The retrieved records from the database searches were combined, and duplicates were eliminated using EndNote X7 (Thomson Reuters, Toronto, ON, Canada). Two reviewers (MR and MJN) independently assessed the records based on their title/abstract and full text to exclude any that were not relevant to the objectives of the study.

107 The studies included in the analysis met the following criteria:

Participants: The patients included in the studies had a diagnosis of ACD, which included individuals with a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease.

Intervention: The intervention being investigated was the use of ezetimibe therapy, either as a standalone treatment or in combination with other lipid-lowering therapies.

115 *Comparison:* patients who received standard treatment or in combination with 116 other lipid-lowering therapies.

117

118 *Outcome:* The primary outcome was the average change observed in LDL-C levels119 when compared to the baseline measurements.

120 Data extraction

Two reviewers (MR and MJN) designed a data extraction form and extracted data from all eligible studies, with differences being resolved by consensus. The following data were extracted: first author's name; year of publication; study duration; type of study; country or countries where the study was conducted; number of patients with ACD; patient age; treatment protocols; demographics (i.e., age, sex, nationality); and treatment outcomes.

127 Quality assessment

The quality assessment of the included studies was conducted by two reviewers 128 (MR and PM) using Cochrane tool [9]. In case of any discrepancies, a third 129 reviewer (MJN) was involved. This tool encompasses various domains, including 130 random sequence generation, allocation concealment, blinding of participants and 131 personnel, blinding of outcome assessors, completeness of outcome data, and other 132 factors such as selective reporting and other potential biases. Each study was 133 categorized as having a low risk of bias when no concerns regarding bias were 134 identified, a high risk of bias when there were concerns about bias, or an unclear 135 risk of bias when there was insufficient information available. 136

137 Data analysis

The statistical analysis was performed using Comprehensive Meta-Analysis 138 software, version 3.0 (Biostat Inc., Englewood, NJ, USA). The weighted mean 139 difference (WMD) was used as the pooled statistic, with a corresponding 95% 140 confidence interval (CI). The degree of heterogeneity among the studies was 141 assessed using the I2 value and p-value. In cases where the statistical heterogeneity 142 between the studies was low (I2 \leq 50% or p \geq 0.1), the fixed-effect model was 143 utilized. Conversely, if a significant level of inter-study heterogeneity was 144 observed (I2 > 50% or p < 0.1), the random-effects model was employed. 145 Cochran's Q test and the I2 statistic were used to assess between-study 146

heterogeneity. To evaluate publication bias, Begg's test was applied, where a P
value of less than 0.05 was considered indicative of statistically significant
publication bias.

150

151 **Results:**

Figure 1 displays the systematic review flow diagram. Through the systematic 152 153 literature review, a total of 20 records meeting the eligibility criteria were identified. These records reported the primary outcome, either the change in LDL-154 C from baseline or the LDL-C level at the endpoint, or both. They provided 155 sufficient independent information for the meta-analysis. The inclusion/exclusion 156 justifications are summarized, and Table 1 lists the 20 studies included in the meta-157 analysis. The table presents details about the study design, duration, baseline 158 demographic characteristics. 159

Although the objective was to evaluate LDL-C lowering with ezetimibe therapy, with or without other LLTs, all the included studies compared combination ezetimibe plus statin therapy with statin monotherapy. The mean age of participants across the studies ranged from 57 to 71 years, depending on the treatment group (Table 1).

165 **Quality assessment**

Regarding the risk of bias across the 20 trials, insufficient detail was provided about the randomization methodology, resulting in an unclear risk of selection bias for random sequence generation and allocation concealment. Other biases were assessed as low in the trials (Table 2).

170

171 *Efficacy of LDL-C Lowering of Ezetimibe*

As indicated in Figure 1, patients receiving combination of statin and ezetimibe were found to have a significant additional reduction in LDL-C (-14.06 mg/dL;

174 95% confidence interval [CI] -18.0 to -10.0, p < 0.0001) than those receiving 175 statin alone.

176 *Fibro-fatty plaque (FFP) volume*

The efficacy of FFP was evaluated in four studies. There was no heterogeneity among the studies (I2 = 58.4%, p = 0.065). Using a random-effects model analysis, it was found that treatment interventions in the study group effectively reduced FFP when compared to the control group, showing a statistically significant difference [WMD = -1.01, 95% CI (-3.6 and 1.6), and p = 0.45], as shown in Figure2.

183

184 Necrotic core (NC) volume

The efficacy of NC was reported in three out of the four research studies. There was no heterogeneity among the studies (I2 = 70.4%, p = 0.03). Using a randomeffects model analysis, the results showed no significant difference in the reduction of NC between the treatment group and the control group [WMD = -5.41, 95% CI (-13.3 and 2.5), and p = 0.18], as shown in Figure 3.

190

191 Change dense calcification (change DC) volume

All research studies examined the efficacy of change DC. There was no heterogeneity among the studies (I2 = 0%, p = 0.42). Using a fixed-effects model analysis, the results showed no significant difference in the reduction of change DC between the treatment group and the control group [WMD = -1.14, 95% CI (-1.4and – 0.8), and p = 0.00], as shown in Figure 4.

197

198

199

200 **Discussion:**

201 Principal findings

In this meta-analysis we demonstrated that, for patients with ACD, ezetimibe added to statin therapy provided an additional reduction of LDL-C compared with statin monotherapy.

205 *Comparisons with other studies*

Our results are consistent with prior evidence on lipid-lowering therapies. For 206 instance, a meta-analysis by Shaya et al showed larger relative in LDL-C by 207 addition of ezetimibe to statin therapy, compared with statin monotherapy [10]. 208 Another meta-analysis demonstrated that ezetimibe significantly decreased 209 coronary atherosclerotic plaque compared to the control group (placebo or statin 210 monotherapy) [11]. Likewise, Toyota et al confirms that all 3 strategies for 211 enhancing LDL-C reduction- i.e. more-intensive statin therapy, adding ezetimibe, 212 and adding PCSK9, could improves clinical outcomes in high atherosclerotic 213 cardiovascular disease [12]. 214

215

216 *Strength and limitations of this study*

The final result of our study is along with the Shava et al. meta-analysis published 217 in 2020 which demonstrated a decreased risk of ACD in patients receiving 218 ezetimibe [10]. However, our study has some strengths and is different in some 219 ways. We also included studies focused on the FFP volume, NC volume and DC 220 volume. Studies in which the sample population had specific comorbidities were 221 excluded to lessen the potential effect of the confounding factors. Also, we 222 excluded the articles in which the full text was not found. Against this, we included 223 eight other studies that not previously included. Our calculated WMD (-14.06, 224 95% CI 18.0-10.0) was a little higher than Shaya et al. (-21.8, CI 95% -26.5-,17.1) 225 but in line with its direction and statistical significance. 226

The major limitation of our study is its originality, as the data on the efficacy of 227 ezetimibe on LDL-C has been known and ascertained for some time and also 228 reported by international guideline. However, an update of data relating to 229 scientific evidence can still have value. Some other limitations of our study are 230 associated with the studies we included and are as follows: First, there have not 231 been any recent clinical trials studies on the topic and the most recent one was 232 233 published in 2021. Further new investigations with a large number of populations are required to elucidate the issue. Second, there were confounding factors in the 234 included studies which we have inability to subgroup analysis, due to insufficient 235 and inconsistent data. Third, the mortality benefits of ezetimibe despite its 236 intensive lowering of LDL-C levels should be investigated. The survival advantage 237 relies on several factors, including the efficacy of the drug, competing risks, off-238 target effects, baseline cardiovascular risk, and follow-up duration of the study. 239

240

241 *Clinical implications*

This systematic review informs decision makers about the benefits of ezetimibe on important cardiovascular outcomes. The key observations are that moderate to high certainty evidence favors ezetimibe for lowering LDL-C levels and. Furthermore, these agents lead to reducing the volume of FFP.

246 *Conclusions*

Our study indicates that the addition of ezetimibe to statin therapy results in a modest yet significant further reduction in LDL-C compared to statin monotherapy. Ezetimibe led to a significant reduction in FFP volume; however, there were no statistically significant differences observed for NC, or change DC volumes.

2	5	2
_	~	-

253 References:

255 256	1.	Kronenberg, F., et al., Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European heart journal, 2022.
257		43 (39): p. 3925-3946.
258 259	2.	Mortensen, M.B. and B.G. Nordestgaard, Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100
260		years: a contemporary primary prevention cohort. The Lancet, 2020. 396 (10263): p. 1644-1652.
261	3.	Ouchi, Y., et al., Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular
262		disease in 75 or older (ewtopia 75) A randomized, controlled trial. Circulation, 2019. 140 (12): p.
263		992-1003.
264	4.	Phan, B.A.P., T.D. Dayspring, and P.P. Toth, Ezetimibe therapy: mechanism of action and clinical
265		update. Vascular health and risk management, 2012: p. 415-427.
266	5.	Vavlukis, M. and A. Vavlukis, Adding ezetimibe to statin therapy: latest evidence and clinical
207	c	Implications. Drugs in context, 2018. 7.
268	Ь.	Murphy, S.A., et al., Reduction in total cardiovascular events with ezetimibe/simvastatin post-
269 270		2016. 67 (4): p. 353-361.
271	7.	Ueda, Y., et al., Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plague—The
272		ZIPANGU Study—, Circulation Journal, 2017, 81 (11); p. 1611-1619.
273	8.	Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses; the
274	•	PRISMA statement Annals of internal medicine 2009 151 (4): p 264-269
275	9	Higgins IP et al. The Cochrane Collaboration's tool for assessing risk of higs in randomised
276	•••	<i>trials.</i> Bmj, 2011. 343 .
277	10.	Shaya, F.T., et al., Lipid-lowering efficacy of ezetimibe in patients with atherosclerotic
278		cardiovascular disease: a systematic review and meta-analyses. American Journal of
279		Cardiovascular Drugs, 2020. 20 : p. 239-248.
280	11.	Chai, B., et al., Meta-analysis and trial sequential analysis of ezetimibe for coronary
281		atherosclerotic plaque compositions. Frontiers in Pharmacology, 2023. 14 : p. 1166762.
282	12.	Toyota, T., et al., More- Versus Less-Intensive Lipid-Lowering Therapy. Circ Cardiovasc Qual
283		Outcomes, 2019. 12 (8): p. e005460.
284	13.	Hougaard, M., et al., Influence of ezetimibe in addition to high-dose atorvastatin therapy on
285		plaque composition in patients with ST-segment elevation myocardial infarction assessed by
286		serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med, 2017.
287		18 (2): p. 110-117.
288	14.	Lee, J.H., et al., Early Effects of Intensive Lipid-Lowering Treatment on Plague Characteristics
289		Assessed by Virtual Histology Intravascular Ultrasound. Yonsei medical journal, 2016. 57(5): p.
290		1087-1094.
291	15.	Kovarnik, T., et al., Virtual histoloav evaluation of atherosclerosis rearession during atorvastatin
292		and ezetimibe administration: HEAVEN study. Circ J. 2012. 76 (1): p. 176-83.
293	16.	Brohet, C., et al., LDL-C agal attainment with the addition of ezetimibe to ongoing simvastation
294		treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin.
295		2005. 21 (4): p. 571-8.

- 29617.Cannon, C.P., et al., *Ezetimibe added to statin therapy after acute coronary syndromes.* New297England Journal of Medicine, 2015. **372**(25): p. 2387-2397.
- 29818.Hibi, K., et al., Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in299Acute Coronary Syndrome. Circ J, 2018. 82(3): p. 757-766.
- Joshi, S., et al., Efficacy of Combination Therapy of Rosuvastatin and Ezetimibe vs Rosuvastatin
 Monotherapy on Lipid Profile of Patients with Coronary Artery Disease. Journal of Clinical &
 Diagnostic Research, 2017. 11(12).
- Masuda, J., et al., *Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.* Int Heart J, 2015. 56(3): p. 278 85.
- 30621.Ran, D., et al., A randomized, controlled comparison of different intensive lipid-lowering307therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS):308Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol, 2017. 235: p. 49-55.
- Ren, Y., et al., Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers
 of inflammation in patients with acute myocardial infarction. Exp Ther Med, 2017. 14(5): p.
 4942-4950.
- 31223.Ueda, Y., et al., Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque313The ZIPANGU Study. Circ J, 2017. 81(11): p. 1611-1619.
- Wang, J., et al., Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid
 artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease.
 Int Angiol, 2017. 36(5): p. 467-473.
- 31725.Wang, X., et al., Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque318in Patients with Coronary Heart Disease. Heart Lung Circ, 2016. 25(5): p. 459-65.
- 31926.West, A.M., et al., The effect of ezetimibe on peripheral arterial atherosclerosis depends upon320statin use at baseline. Atherosclerosis, 2011. **218**(1): p. 156-62.
- 32127.Zou, Y., et al. Effect of Ezetimibe Combined with Low-dose Atorvastain Calcium on Carotid322Atherosclerosis in Elderly Patients with Coronary Heart Disease. in Journal of the American323Geriatrics Society. 2016. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
- 32428.El-Tamalawy, M.M., et al., Effect of Combination Therapy of Ezetimibe and Atorvastatin on325Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. J Clin326Pharmacol, 2018. 58(1): p. 34-41.
- 32729.Klassen, A., et al., Evaluation of two highly effective lipid-lowering therapies in subjects with328acute myocardial infarction. Sci Rep, 2021. **11**(1): p. 15973.
- 32930.Oh, P.C., et al., Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to330Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. Am J Cardiol, 2021. 154: p. 22-28.
- 31. Pinto, L.C.S., et al., Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. Lipids Health Dis, 2021.
 333 20(1): p. 124.
- 334 32. Blom, D.J., et al., A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J
 335 Med, 2014. **370**(19): p. 1809-19.
- 336
- 337
- 338



345	Figure 1. Flow chart of study selection for inclusion in the systematic review.
346	
347	
348	
349	
350	

351

Table 1. Demographics and baseline characteristics of patients included in the meta-analysis according to study and treatment group

		Sample size	Age	Intervention		D. I
Authors	Study design	T/C	Т	Т	С	Duration
Hougaard, 2017 [13]	RCT	43/44	55.3 ± 11.0	EZ (10) + AT (80)	PL (10) + AT (80)	12 months
Jung-(2016) [14]	RCT	34/36	60.9 ± 10.9 EZ (10 (40		PR (20)	03 months
Kovarnik(201 2) [15]	RCT	42/47	63.5 ± 9.3	EZ (10) + AT (80)	AT (10)	12 months
Brohet et al. (2005) [16]	RCT	208/210	63.6±11.1	EZE 10 mg QD+ SIM 10/20 mg QD	SIM 10/20 mg QD	6 weeks
Cannon et al. (2015) [17]	RCT	9067/9077	63.6±9.7	EZE 10 mg QD + SIM 40–80 mg QD	IM 40–80 mg QD	6 years
Hibi et al. (2018) [18]	RCT	50/53	63± 10.0	EZE 10 mg QD+PITA 2 mg	PITA 2 mg QD	10 months
Joshi et al. (2017) [19]	RCT	40/40	60.3±9.8	EZE 10 mg QD +ROSU 10 mg QD	ROSU 10 mg QD	24 weeks

Masuda et al. (2015) [20]	RCT	21/19	64.0± 7.9	EZE 10 mg QD + ROSU 5 mg QD	ROSU 5 mg QD	6 months
Ran et al. (2017) [21]	RCT	42/42	60.4± 8.2	EZE 10 mg QD +ROSU 10 mg QD	ROSU 10 mg QD	10 weeks
Ren et al. (2017) [22]	RCT	55/58	57.3± 1.5	EZE 10 mg QD +ROSU 10 mg QD	ROSU 10 mg QD	12 months
Ueda et al. (2017) [23]	RCT	54/54	71±8.0	EZE 10 mg QD + ATOR 10–20 mg QD	ATOR 10–20 mg QD	9 months
Wang et al. (2017) [24]	RCT	51/49	58±10.0	EZE 10 mg QD +ATOR 20 mg QD	ATOR 20 mg QD	12 months
Wang et al. (2016) [25]	RCT	50/48	63±10.0	EZE 10 mg QD +ROSU 10 mg QD	ROSU 10 mg QD	12 months
West et al. (2011) [26]	RCT	18/33	62 ± 8.0	EZE 10 mg QD+SIM 40 mg QD	EZE 10 mg QD	2 years
Zou et al. (2016) [27]	RCT	40/40	69.3±5.8	EZE 10 mg QD +ATOR 10 mg QD	ATOR 10 mg QD	12 months
El-Tamalawy et al (2018) [28]	RCT	33/32	61 ± 7.1	EZE 10 mg/day + ATOR 40 mg daily	ATOR 80 mg daily	3 months
Klassen et al(2021) [29]	RCT	10/10	62 (59–64)	EZE 10 mg QD + ROSU 20 mg QD or SIM 40 mg	ROSU 20 mg QD	1 month
Oh et al(2021) [30]	RCT	18/19	56.3 § 7.1	ATO10 mg + EZE10 mg	ATO 40 mg	12 months

Pinto et al(2021) [31]	RCT	50/51	59 (52–65)	EZE 10mg+SIM 40 mg	ROSU 20 mg	1 month		
Blom et al(2014) [32]	RCT	63/73	55.9±9.0	EZE 10 mg+ ATOR 80 mg	ATOR 80 mg	1-2 months		
T, treatment group; C, control group; EZ, ezetimibe; ATOR, atorvastatin; SIM, simvastatin								

Table 2. Quality assessment

Author	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	
Brohet et al	L	U	L	U	L	
Cannon et al	U	U	U	U	L	
Hibi et al	L	U	Н	L	L	
Joshi et al	L	U	U	U	L	
Masuda et al	L	L	Н	Н	L	
Ran et al	L	U	Н	U	L	
Ren et al	L	U	U	U	L	
Ueda et al	L	U	Н	L	L	
Wang 2017 et al	U	U	U	U	L	
Wang 2016 et al	L	U	U	U	L	
West et al	L	U	L	L	L	
Zou et al	U	U	U	U	L	
El-Tamalawy et al	L	U	L	L	L	
Klassen et al	L	U	L	L	L	
Oh et al	L	U	L	L	L	
Zou et al	U	U	U	U	L	
El-Tamalawy et al	L	U	L	L	L	
Klassen et al	L	U	L	L	L	
Oh et al	L	U	L	L	L	
Pinto et al	L	U	L	L	L	
Blom et al	L	U	L	L	L	
Mikkle et al	L	U	L	L	L	
Jung et al	L	U	L	L	L	
Kovarnik et al	L	Н	L	L	L	

359 L; low, H; high, U; unclear

Study name	Stati	stics for	each stu	dy		Difference	in means				
	Difference in means	Lower limit	Upper limit	p-Value						Relative weight	Relativ weigh
Brohet	-22.900	-36.443	-9.357	0.001			-			3.85	
Cannon	-16.700	-26.646	-6.754	0.001		+_∎	-			4.85	
Joshi	-11.700	-18.406	-4.994	0.001		_ ⊣	∎-			5.81	
Masouda	-19.000	-29.444	-8.556	0.000		+æ_	-			4.70	
Ran	-21.300	-33.531	-9.069	0.001			-			4.20	
Ren	-11.600	-18.308	-4.892	0.001		_ ⊣	-			5.81	
Ueda	-14.000	-22.107	-5.893	0.001			┣─ │			5.40	
Wang 2017	-17.400	-27.452	-7.348	0.001		+=	-			4.82	
Wang 2016	-24.000	-37.856	-10.144	0.001			-			3.77	
West	-7.000	-10.919	-3.081	0.000						6.52	
Hibi	-16.900	-26.672	-7.128	0.001		- +-∎	-			4.90	
Zou	-35.500	-55.847	-15.153	0.001	<hr/>	╼┼╴				2.47	
El-Tamalawy	-29.000	-45.467	-12.533	0.001	I –	━━	-			3.17	
Klassen	-8.000	-11.998	-4.002	0.000						6.50	
Oh	2.700	1.226	4.174	0.000						6.89	
Pinto	-3.250	-5.128	-1.372	0.001						6.85	
Blom	-23.600	-37.348	-9.852	0.001			-			3.80	
Jung	-24.100	-37.833	-10.367	0.001			-			3.80	
Kovarnik 2012	-10.800	-17.015	-4.585	0.001		-	▇─│			5.95	
Hougaard	-10.800	-16.990	-4.610	0.001		-	▇─│			5.95	
	-14.066	-18.043	-10.089	0.000		- ◀					
					-50.00	-25.00	0.00	25.00	50.00		
					E	zetimibe+St	atin	Statin			

- Figure 1.Treatment difference in mean LDL-C change (mg/dL) from baseline between combination
- ezetimibe plus statin therapy and statin monotherapy comparator at 6 months or at the reported timepoint
 closest to 6 months



- Figure 2, Forst plot for Fibro-Fatty plaque volume



- 379 Figure 3, The forest plot for necrotic core volume





- 390
- 391